Lonza Appoints Samanta Cimitan as Chief Commercial Officer (CCO) to Enhance Customer Engagement and Accelerate Growth

September 6, 2026

Fierce Pharma Switzerland

Overview

Lonza announced the appointment of Samanta Cimitan as its new Chief Commercial Officer (CCO), effective January 1, 2027. This strategic move aims to integrate Lonza’s strategic enterprise account management, global marketing, and commercial excellence functions to enhance customer engagement. This leadership reinforcement builds upon the robust sales growth achieved in H1 2026, solidifying the company’s market position as a leading biomanufacturing CDMO.

In Depth

Key Findings

Lonza, a leader in the biomanufacturing industry, made a significant organizational announcement, appointing Samanta Cimitan to the newly created role of Chief Commercial Officer (CCO), effective January 1, 2027. This strategic move is intended to integrate the company’s customer engagement efforts and bolster its global commercial strategy, thereby accelerating sustained growth.

Technical / Clinical Details

With Samanta Cimitan as CCO, Lonza will centralize its strategic enterprise account management, global marketing, and commercial excellence initiatives. This is expected to optimize interactions with clients and enhance the efficiency of its Contract Development and Manufacturing Organization (CDMO) service offerings across various modalities, including biologics, small molecules, and cell and gene therapies. Cimitan’s extensive industry experience will foster synergies across Lonza’s business units, enabling the provision of more integrated solutions to clients with complex pharmaceutical pipelines. This signifies a strengthening of the organizational structure to leverage Lonza’s technological depth and scale, including in the cell and gene therapy sector, and to respond more swiftly to market demands.

Background & Context

The global biomanufacturing market is experiencing increasing demand for CDMOs, driven by accelerating drug development, the emergence of complex modalities, and a growing trend among pharmaceutical companies to outsource. In this highly competitive environment, strong client relationship building and effective commercial strategies are indispensable for maintaining market leadership. Lonza has long established itself as a premier CDMO provider, thanks to its extensive manufacturing capabilities and technical expertise. The creation of the CCO role signals a strategic shift to adapt to market evolution and further strengthen a client-centric business model. The robust sales growth in H1 2026 provides a solid financial foundation for this strategy.

Strategic Significance & Outlook

Under Samanta Cimitan’s leadership as CCO, Lonza will refine its commercial strategies, pursuing both the expansion of its customer base and the deepening of relationships with existing clients. This organizational restructuring is anticipated to play a crucial role in enabling the company to more effectively support pharmaceutical and biotechnology sponsors across diverse modalities, further solidifying its unique position in the market. Particularly in high-growth areas like cell and gene therapy, an integrated commercial approach will be key to rapidly bringing innovative treatments to market and to patients. This move by Lonza has the potential to set new standards for commercial approaches across the CDMO industry.

Source: https://www.fiercepharma.com/marketing/cdmo-lonza-hones-commercial-focus-seasoned-exec-returning-newly-created-role

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.